Search Results

51 - 60 of 490 items :

  • "prostate cancer" x
Clear All
Complications of Transrectal Prostate Biopsy

References 1. Klečka J, Holubec L, Pešta M, Hora M, Topolčan O, Eret V. Nádorové markery karcinómu prostaty. Ces Urol 2008; 12(3): 173-185. 2. Sigebara K, Miyagi T, Nakashima T, Shimamura M. Acute bacterial prostatitis after transrectal nedele biopsy: clinical analysis. J Clin Chemother 2008; 14: 40-43. 3. Webb NR, Woo HH. Antibiotic prophylaxis for prostate biopsy. BJU International 2002; 89: 824-828. 4. EAU Guidelines 2013; Prostate cancer; 6. p: 18. 5. Ecke TH, Gunia S, Bartel

Open access
A Monte Carlo study on the radio-sensitization effect of gold nanoparticles in brachytherapy of prostate by 103Pd seeds

characterization of the first AMIRS 103Pd brachytherapy source. Appl Radiat Isot 2008;66(12):1856-60. [32] Kim YJ, Park JH, Yun IH, Kim YS. A prospective comparison of acute intestinal toxicity following whole pelvic versus small field intensity-modulated radiotherapy for prostate cancer. Onco Targets Ther. 2016;9:1319-25. [33] Xie WZ, Friedland WF, Li WB, et al. Simulation on the molecular radiosensitization effect of gold nanoparticles in cells irradiated by x-rays. Phys Med Biol 2015; 21;60(16):6195-212. [34] Yang CJ, Chithrani DB. Nuclear Targeting of Gold

Open access
Arylsulfatase A: An Important Metabolic Factor in Pathophysiology of Different Diseases


Arylsulfatase A (ARSA) is a lysosomal enzyme that plays an important role in catalysis of degradation of cerebrosidesulphate. The deficiency of this lysosomal enzyme causes an autosomal recessive disorder, called metachromatic leucodystrophy. However, a low ARSA activity can be observed in clinically healthy people, called ARSA pseudodeficiency. In our study we investigated the possible linkage between ARSA activity and sulfatide deficiency causing characteristic aspects of degenerative diseases, such as end stage kidney disease, type 2 Diabetes mellitus, Parkinson syndrome, prostate cancer and HIV (Human Immunodeficiency Virus) infection. We used a spectrophotometric method to determine the activity of ARSA. This method of enzyme dosage is based on a 4 hour long hydrolysis of the ARSA enzyme on 4-nitrocatechol sulfate (p-NCS) substrate. The unit of this measurement is nmol/ml/4h. Our findings show significant values in type 2 diabetes, Parkinson syndrome and chronic kidney disease. The importance of sulfatide in these diseases is well-known, thus presumably the variation of the ARSA’s activity might play an important role in the pathophysiology of these diseases, involving a vicious cycle between sulfatide degradation andthese diseases.

Open access
Optimal planning strategy among various arc arrangements for prostate stereotactic body radiotherapy with volumetric modulated arc therapy technique

Introduction Prostate cancer is the most common cancer in men, accounting for over one fifth of male cancer diagnoses, with the number of prostate cancer patients rapidly increasing. Various radiotherapy techniques for treating prostate cancer have been considered effective noninvasive treatment options, especially for elderly patients and those unfit for surgery. 1 - 3 Radiation therapy options for prostate cancer include external beam radiation therapy (EBRT) and brachytherapy. Volumetric modulated arc therapy (VMAT) and intensity-modulated radiation

Open access
Sodium-glucose cotransporters: new targets of cancer therapy?

50. Ghezzi C, Wright EM. Regulation of the human Na+- dependent glucose cotransporter hSGLT2. Am J Physiol-Cell Ph 2012;303:C348-54. doi: 10.1152/ajpcell.00115.2012 51. Siegel RL, Miller KD, Jemal A. Cancer Statistics. CA Cancer J Clin 2017;67:7-30. doi: 10.3322/caac.21387 52. Vaz CV, Marques R, Alves MG, Oliveira PF, Cavaco JE, Maia CJ, Socorro S. Androgens enhance the glycolytic metabolism and lactate export in prostate cancer cells by modulating the expression of GLUT1, GLUT3, PFK, LDH and MCT4 genes. J Cancer Res Clin Oncol

Open access
Initial experience of using an iron-containing fiducial marker for radiotherapy of prostate cancer: Advantages in the visualization of markers in Computed Tomography and Magnetic Resonance Imaging

;42(5):2638-2647. [4] Tanaka O, Hayashi S, Matsuo M, et al. Comparison of MRI-based and CT/MRI fusion-based postimplant dosimetric analysis of prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;66(2):597-602. [5] Tanaka O, Hattori M, Hirose S. Comparison of the MRI sequences in ideal fiducial marker-based radiotherapy for prostate cancer. Radiother Oncol. 2016;119(Supplement1):S858-S859.

Open access
Measurements of doses from photon beam irradiation and scattered neutrons in an anthropomorphic phantom model of prostate cancer: a comparison between 3DCRT, IMRT and tomotherapy

and neck radiotherapy using IMRT and 3D-CRT. Radiol. Oncol ., 46 (4), 328–336. 10. Van den Heuvel, F., Defraene, G., Crijns, W., & Bogaerts, R. (2012). Out-of-field contributions for IMRT and volumetric modulated arc therapy measured using gafchromic films and compared to calculations using a superposition/convolution based treatment planning system. Radiother. Oncol ., 105 (1), 127–132. 11. Skórska, M., & Piotrowski, T. (2013). Optimization of treatment planning parameters used in tomotherapy for prostate cancer patients. Phys. Med ., 29 (3), 273

Open access
Evaluation of safety and analgesic consumption in patients with advanced cancer treated with zoledronic acid

with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999; 161: 1219-22. 5. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-6. 6. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458

Open access
Role of 18F-choline PET/CT in evaluation of patients with prostate carcinoma

References Reske SN. Nuclear imaging of prostate cancer: current status. Urologe A 2007; 46 : 1485-99. Kragelj B. Increased late urinary toxicity with whole pelvic radiotherapy after prostatectomy. Radiol Oncol 2009; 43 : 88-96. Avazpour I, Roslan RE, Bayat P, Saripan MI, Nordin AJ, Abdullah RSAR. Segmenting CT images of bronchogenic carcinoma with bone metastases using PET intensity markers approach. Radiol Oncol 2009; 43 : 180-6. Naji M, Hodolic

Open access
Dynamics of Prostate-Specific Antigen Levels During Treatment with Testosterone Undecanoate in Patients with Type 2 Diabetes Mellitus

References 1. Crawford ED, Abrahamsson PA . PSA-based screening for prostate cancer: how does it compare with other cancer screening tests? Eur Urol 54: 262-273, 2008 . 2. Heinlein CA, Chang C . Androgen receptor in prostate cancer. Endocr Rev 25: 276-308, 2004. 3. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28: 251-265, 1996. 4. Velcheti V, Karnik S, Bardot SF, Prakash O . Pathogenesis

Open access